

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.¹

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Gulf Manganese Corporation Limited

ABN

73 059 954 317

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

- 1) Fully Paid Ordinary Shares
- 2) Performance Rights (Employee)
- 3) Fully Paid Ordinary Shares

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

- 1) 64,000,000
- 2) 1,200,000
- 3) 1,200,000

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

- 1) Fully Paid Ordinary Shares
- 2) Performance Rights (Employee) which vested on 3 October 2019
- 3) Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

<p>4 Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional ⁺securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>1) Yes 2) No 3) Yes</p>
<p>5 Issue price or consideration</p>	<p>Nil</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>1) Placement to Acuity 2) Issued to an employee under the Company's Long-Term Incentive Plan approved by shareholders on 13 September 2019 3) Vesting of Performance Rights</p>
<p>6a Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the ⁺securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>Yes</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>19 November 2018</p>

6c	Number of +securities issued without security holder approval under rule 7.1	
6d	Number of +securities issued with security holder approval under rule 7.1A	1) 64,000,000
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of +securities issued under an exception in rule 7.2	2) Performance Rights issued under Listing Rule 7.2 exception 9 3) Shares issued upon conversion of Performance Rights under Listing Rule 7.2 exception 4
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	1) 64,000,000 shares were issued under rule 7.1A at an issue price of \$0.006 per share. The 15 trading day VWAP ending on 2 October was \$0.0060. 75% of this VWAP is equal to \$0.0045 being lower than the issue price of \$0.006.
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1.

+ See chapter 19 for defined terms.

7	<p>⁺Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	3 October 2019
---	---	----------------

8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	Number	⁺ Class
		5,044,848,331	Fully Paid Ordinary Shares

	Number	+Class
9		Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)
	50,000,000	Unlisted Options expiring 5 September 2021 at \$0.02
	24,000,000	Unlisted Options expiring 5 September 2021 at \$0.02 (ECSOP)
	18,000,000	Performance Rights expiring 28 November 2019 (Directors)
	16,000,000	Performance Rights expiring 28 November 2019 (Employees)
	31,500,001	Performance Rights vesting 20 December 2020 (Directors)
	25,000,000	Unlisted Options expiring 31 December 2020 at \$0.02
	25,000,000	Unlisted Options expiring 31 December 2020 at \$0.03
	6,725,083	Performance Rights vesting 5 March 2021 (Directors)
	6,725,083	Performance Rights vesting 5 March 2022 (Directors)
	1,500,000	Performance Rights vesting 5 March 2022 (Employees)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11 Is security holder approval required?

N/A

12 Is the issue renounceable or non-renounceable?

N/A

+ See chapter 19 for defined terms.

13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	<p>Names of countries in which the entity has security holders who will not be sent new offer documents</p> <p><small>Note: Security holders must be told how their entitlements are to be dealt with.</small></p> <p><small>Cross reference: rule 7.7.</small></p>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities
(tick one)

⁺ See chapter 19 for defined terms.

(a) ☒ ⁺Securities described in Part 1

(b) ☐ All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☐ If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 ☐ If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 ☐ A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

38 Number of ⁺securities for which ⁺quotation is sought

N/A

39 ⁺Class of ⁺securities for which quotation is sought

N/A

40	<p>Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional ⁺securities do not rank equally, please state:</p> <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A	
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)</p>	N/A	
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	⁺ Class
		N/A	N/A

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those ⁺securities should not be granted ⁺quotation.

⁺ See chapter 19 for defined terms.

- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:

..... Date: **4 October 2019**

Hamish Bohannan

(Managing Director and CEO)

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	2,862,447,239
Add the following: <ul style="list-style-type: none"> Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	10,000,000 shares issued in October 2018 after exercise of listed options (LR 7.2 Ex 4) 6,534,200 shares issued 17/12/18 after exercise of listed options (LR 7.2 Ex 4) 100,000,000 shares issued 17/12/18 with shareholder approval on 19/11/18 (LR7.1) 110,000,000 shares issued 24/12/18 and ratified on 28/2/19 (LR 7.4) 5,000,000 shares issued 8/1/19 after exercise of listed options (LR 7.2 Ex 4) 133,333,333 shares issued 15/1/19 upon conversion of convertible notes (LR 7.2 Ex 4) 241,815,011 shares issued 15/1/19 and ratified on 28/2/19 (LR 7.4) 10,000,000 shares issued 24/1/19 and ratified on 28/2/19 (LR 7.4) 3,000,000 shares issued 1/3/19 after exercise of listed options (LR 7.2 Ex 4) 8,750,000 shares issued 7/3/18 with shareholder approval on 19/11/18 (LR7.2 Ex 14) 4,100,000 shares issued 12/03/19 after exercise of listed options (LR 7.2 Ex 4)

+ See chapter 19 for defined terms.

	<p>33,794,007 shares issued between 22/03/19 and 27/03/19 after exercise of listed options (LR 7.2 Ex 4)</p> <p>18,001,133 shares issued 7/3/19 upon vesting of performance rights (LR 7.2 Ex 4)</p> <p>18,750,000 shares issued 28/3/19 with shareholder approval on 28/2/19 (LR7.2 Ex 14)</p> <p>9,086,610 shares issued on 29/3/19 after exercise of listed options (LR 7.2 Ex 4)</p> <p>61,540,900 shares issued between 1 April 2019 and 5 April 2019 after exercise of listed options (LR 7.2 Ex 4)</p> <p>57,858,959 shares issued between 8 April 2019 and 11 April 2019 after exercise of listed options (LR 7.2 Ex 4)</p> <p>127,143,197 shares issued between 12 April 2019 and 16 April 2019 after exercise of listed options (LR 7.2 Ex 4)</p> <p>163,841,131 shares issued between 17 April 2019 and 1 May 2019 after exercise of listed options (LR 7.2 Ex 4)</p> <p>27,489,334 shares issued 22/7/19 and 29/7/19 upon vesting of performance rights (LR 7.2 Ex 4)</p> <p>34,321,500 shares issued 7/3/19 under an STI Plan and ratified on 13/9/19 (LR 7.2 Ex4)</p> <p>20,000,000 shares issued 8/3/19 for services rendered by a consultant and ratified on 13/9/19 (LR 7.2 Ex4)</p> <p>46,402,600 shares issued on 29/3/19 in consideration for services rendered by a contractor ratified on 13/9/19 (LR 7.2 Ex4)</p> <p>280,831,747 shares issued on 24/5/19 under a share placement ratified on 13/9/19 (LR 7.2 Ex4)</p> <p>107,196,000 shares issued on 5/6/19 under a share placement ratified on 13/9/19 (LR 7.2 Ex4)</p> <p>62,500,000 shares issued on 13/2/19 to raise \$500,000 equity at a price of \$0.008 ratified on 13/9/19 (LR 7.4)</p> <p>304,168,253 shares issued on 24/5/19 under a share placement and ratified on 13/9/19 (LR7.4)</p> <p>1,200,000 shares issued on 3/10/19 upon vesting of performance rights (LR 7.2 Ex 4)</p>
--	--

Subtract the number of fully paid +ordinary securities cancelled during that 12m period	NIL
“A”	4,869,105,154

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>Note: this value cannot be changed]</i>
Multiply “A” by 0.15	730,365,773
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>18,283,333 shares issued 21/1/19 upon conversion of loans</p> <p>2,466,667 shares issued 1/3/19 upon conversion of loans</p> <p>1,338,750 shares issued 7/3/19 under an STI Plan</p> <p>7,142,857 shares issued 8/3/19 upon conversion of loans</p> <p>25,000,000 unlisted options issued at \$0.02 and expiring on 31/12/19 granted on 8/3/19 for services rendered by a consultant</p> <p>25,000,000 unlisted options issued at \$0.03 and expiring on 31/12/19 granted on 8/3/19 for services rendered by a consultant</p> <p>1,428,571 shares issued on 29/3/19 upon conversion of a loan</p>

+ See chapter 19 for defined terms.

	<p>12,200,000 shares issued on 26/4/19 for services rendered by a consultant</p> <p>41,891,333 shares issued on 17/09/19 for shares issued under an STI Plan</p>
“C”	134,751,511
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	730,365,773
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	134,751,511
<p>Total [“A” x 0.15] – “C”</p> <p>Note: this is the remaining placement capacity under rule 7.1</p>	595,611,262

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
<p>“A”</p> <p><i>Note: number must be same as shown in Step 1 of Part 1</i></p>	4,869,105,154
Step 2: Calculate 10% of “A”	
<p>“D”</p> <p><i>Note: this value cannot be changed</i></p>	0.10
Multiply “A” by 0.10	486,910,515

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
<p>Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p>Notes:</p> <ul style="list-style-type: none"> • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items 	<p>13,658,333 shares issued 13/2/19 upon conversion of loans</p> <p>64,000,000 shares issued 3/10/19 under share placement to Acuity</p>
“E”	77,658,333
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
<p>“A” x 0.10</p> <p>Note: number must be same as shown in Step 2</p>	486,790,515
<p>Subtract “E”</p> <p>Note: number must be same as shown in Step 3</p>	77,658,333
<p>Total [“A” x 0.10] – “E”</p>	<p>409,132,182</p> <p>Note: this is the remaining placement capacity under rule 7.1A</p>

+ See chapter 19 for defined terms.